Literature DB >> 10099497

High-throughput screening of historic collections: observations on file size, biological targets, and file diversity.

R W Spencer1.   

Abstract

At Pfizer Central Research, high-throughput screening has been an important source of new leads for drug discovery for a decade. Our experience with over 150 high-throughput screens can address questions about necessary file size, how well particular biological targets fare (with particular reference to protein-protein interactions), and what file diversity means in practice. Copyright 1998 John Wiley & Sons, Inc.

Mesh:

Substances:

Year:  1998        PMID: 10099497

Source DB:  PubMed          Journal:  Biotechnol Bioeng        ISSN: 0006-3592            Impact factor:   4.530


  21 in total

Review 1.  Search and discovery strategies for biotechnology: the paradigm shift.

Authors:  A T Bull; A C Ward; M Goodfellow
Journal:  Microbiol Mol Biol Rev       Date:  2000-09       Impact factor: 11.056

Review 2.  NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development.

Authors:  John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman
Journal:  Psychopharmacology (Berl)       Date:  2003-09-02       Impact factor: 4.530

3.  Designing human m1 muscarinic receptor-targeted hydrophobic eigenmode matched peptides as functional modulators.

Authors:  Karen A Selz; Arnold J Mandell; Michael F Shlesinger; Vani Arcuragi; Michael J Owens
Journal:  Biophys J       Date:  2004-03       Impact factor: 4.033

Review 4.  Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery.

Authors:  Tom L Blundell; Bancinyane L Sibanda; Rinaldo Wander Montalvão; Suzanne Brewerton; Vijayalakshmi Chelliah; Catherine L Worth; Nicholas J Harmer; Owen Davies; David Burke
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2006-03-29       Impact factor: 6.237

5.  Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.

Authors:  Kerim Babaoglu; Anton Simeonov; John J Irwin; Michael E Nelson; Brian Feng; Craig J Thomas; Laura Cancian; M Paola Costi; David A Maltby; Ajit Jadhav; James Inglese; Christopher P Austin; Brian K Shoichet
Journal:  J Med Chem       Date:  2008-03-12       Impact factor: 7.446

6.  Idea2Data: Toward a New Paradigm for Drug Discovery.

Authors:  Christos A Nicolaou; Christine Humblet; Hong Hu; Eva M Martin; Frank C Dorsey; Thomas M Castle; Keith Ian Burton; Haitao Hu; Jorg Hendle; Michael J Hickey; Joel Duerksen; Jibo Wang; Jon A Erickson
Journal:  ACS Med Chem Lett       Date:  2019-02-04       Impact factor: 4.345

7.  Plate-based diversity subset screening: an efficient paradigm for high throughput screening of a large screening file.

Authors:  Andrew S Bell; Joseph Bradley; Jeremy R Everett; Michelle Knight; Jens Loesel; John Mathias; David McLoughlin; James Mills; Robert E Sharp; Christine Williams; Terence P Wood
Journal:  Mol Divers       Date:  2013-04-05       Impact factor: 2.943

8.  Robust generation of lead compounds for protein-protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists.

Authors:  Anna Czarna; Barbara Beck; Stuti Srivastava; Grzegorz M Popowicz; Siglinde Wolf; Yijun Huang; Michal Bista; Tad A Holak; Alexander Dömling
Journal:  Angew Chem Int Ed Engl       Date:  2010-07-19       Impact factor: 15.336

Review 9.  Development of Protein-Protein Interaction Inhibitors for the Treatment of Infectious Diseases.

Authors:  Andrew F Voter; James L Keck
Journal:  Adv Protein Chem Struct Biol       Date:  2017-08-24       Impact factor: 3.507

10.  Quantifying biogenic bias in screening libraries.

Authors:  Jérôme Hert; John J Irwin; Christian Laggner; Michael J Keiser; Brian K Shoichet
Journal:  Nat Chem Biol       Date:  2009-05-31       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.